Sichuan Goldstone Asia Pharmaceutical Inc - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for Sichuan Goldstone Asia Pharmaceutical Inc are displayed. The analysis of Sichuan Goldstone Asia Pharmaceutical Inc incorporates data from across the internet as well as from available filings by Sichuan Goldstone Asia Pharmaceutical Inc. This webpage contains a Q&A section for Sichuan Goldstone Asia Pharmaceutical Inc.
Sichuan Goldstone Asia Pharmaceutical Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Sichuan Goldstone Asia Pharmaceutical Inc | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Sichuan Goldstone Asia Pharmaceutical Inc have an accelerator or VC vehicle to help deliver innovation?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose current and historical energy intensity?
Does Sichuan Goldstone Asia Pharmaceutical Inc report the average age of the workforce?
Does Sichuan Goldstone Asia Pharmaceutical Inc reference operational or capital allocation in relation to climate change?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose its ethnicity pay gap?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose cybersecurity risks?
Does Sichuan Goldstone Asia Pharmaceutical Inc offer flexible work?
Does Sichuan Goldstone Asia Pharmaceutical Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose the number of employees in R&D functions?
Does Sichuan Goldstone Asia Pharmaceutical Inc conduct supply chain audits?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Sichuan Goldstone Asia Pharmaceutical Inc conduct 360 degree staff reviews?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose the individual responsible for D&I?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose current and / or historical scope 2 emissions?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose water use targets?
Does Sichuan Goldstone Asia Pharmaceutical Inc have careers partnerships with academic institutions?
Did Sichuan Goldstone Asia Pharmaceutical Inc have a product recall in the last two years?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose incidents of discrimination?
Does Sichuan Goldstone Asia Pharmaceutical Inc allow for Work Councils/Collective Agreements to be formed?
Has Sichuan Goldstone Asia Pharmaceutical Inc issued a profit warning in the past 24 months?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose parental leave metrics?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose climate scenario or pathway analysis?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose the pay ratio of women to men?
Does Sichuan Goldstone Asia Pharmaceutical Inc support suppliers with sustainability related research and development?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Sichuan Goldstone Asia Pharmaceutical Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Sichuan Goldstone Asia Pharmaceutical Inc involved in embryonic stem cell research?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose GHG and Air Emissions intensity?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose its waste policy?
Does Sichuan Goldstone Asia Pharmaceutical Inc report according to TCFD requirements?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose energy use targets?
Does Sichuan Goldstone Asia Pharmaceutical Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Sichuan Goldstone Asia Pharmaceutical Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Sichuan Goldstone Asia Pharmaceutical Inc
These potential risks are based on the size, segment and geographies of the company.
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, manufacture, and sale of medicines and health products in China and internationally. The company offers various pharmaceutical preparations and APIs; Chinese and western pharmaceutical preparations and raw materials; and tablets, capsules, dietary supplements, vitamin products, OTC products, and prescription drugs. It also trades in various pharmaceutical products, such as Chinese herbal medicine materials, Chinese patent medicines, Chinese herbal pieces, chemical raw materials, pharmaceutical preparations, antibiotic preparations, biochemical drugs, dietary supplements, and toxic drugs for medical use, medical devices, etc.; and sells adult drug products under the Quike brand and children's general medicine products under the Mini-Quike brand name. In addition, the company researches, develops, manufactures, and sells plastic composite pipe and vacuum coating machines. Further, it offers reinforced pipe equipment, such as steel reinforced corrugated pipes, reinforced composite polyethylene pipes, fiberglass reinforced RTP pipes, steel reinforced large diameter pipes, steel reinforced corrugated pipe socket and spigot making machines, abrasion resistant industries pipes, extrusion pipe fittings, and perforated steel reinforced polyethylene composite pipes. Additionally, the company provides vacuum coating equipment, including low-emissivity glass coating lines, reflect glass magnetron sputtering coating lines, magnetron sputtering mirror coating production lines, vacuum sputter systems for automotive car mirrors, ITO/TCO glass coating machines, sputtering metallization machines, optical lens coating machines, roll web metallization machines, and air-to-air solar absorption strip sputtering production line; and smart parking equipment. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 2001 and is based in Chengdu, China.